Literature DB >> 33774187

Why are immune adverse events so common with checkpoint inhibitor therapy?

Taras Lyubchenko1, Donald Y M Leung2, Elena Goleva2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33774187      PMCID： PMC8670739          DOI： 10.1016/j.anai.2021.03.016

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.248


× No keyword cloud information.
  5 in total

1.  T-cell tolerance: central and peripheral.

Authors:  Yan Xing; Kristin A Hogquist
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

2.  Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes.

Authors:  Ganna A Liubchenko; Holly C Appleberry; Christopher C Striebich; Karen E Franklin; Lezlie A Derber; V Michael Holers; Taras Lyubchenko
Journal:  J Autoimmun       Date:  2012-10-08       Impact factor: 7.094

3.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Authors:  Julie R Brahmer; Christina Lacchetti; John A Thompson
Journal:  J Oncol Pract       Date:  2018-03-08       Impact factor: 3.840

Review 4.  The diverse functions of the PD1 inhibitory pathway.

Authors:  Arlene H Sharpe; Kristen E Pauken
Journal:  Nat Rev Immunol       Date:  2017-11-13       Impact factor: 53.106

5.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Authors:  Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777
  5 in total
  1 in total

Review 1.  Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.

Authors:  Elena Goleva; Taras Lyubchenko; Lukas Kraehenbuehl; Mario E Lacouture; Donald Y M Leung; Jeffrey A Kern
Journal:  Ann Allergy Asthma Immunol       Date:  2021-03-11       Impact factor: 6.248
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.